Sino biopharmaceutical begins phase 1 trial for LM-2417

Sino Biopharmaceutical Limited announced the successful enrollment of the first patient in the Phase 1 clinical trial for LM-2417, a NaPi2b/4-1BB bispecific antibody. Developed by LaNova Medicines Limited, a wholly-owned subsidiary, LM-2417 is a National Class 1 innovative drug, marking its official entry into clinical development.

LM-2417, developed on LaNova Medicines' proprietary conditionally activated 4-1BB platform, is designed to specifically bind NaPi2b on tumor cells and 4-1BB on immune cells. This mechanism aims to precisely activate immune cells within the tumor microenvironment, enhancing anti-tumor effects while minimizing toxicity risks. Preclinical data indicates LM-2417 induces durable anti-tumor immune memory and shows synergy with other immunotherapeutic agents.

The open-label, dose escalation, and dose expansion Phase I/II clinical trial will evaluate the safety, tolerability, pharmacokinetic characteristics, and preliminary efficacy of LM-2417 as a monotherapy or in combination with other anti-tumor drugs in patients with advanced malignant solid tumors. The company anticipates rapidly advancing this project to bring new immunotherapy options to patients.